As of June 13, 2025, Cytodyn Inc (CYDY) reports a Net Margin of -79255.64%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Cytodyn Inc's Net Margin
Over recent years, Cytodyn Inc's Net Margin has shown limited historical data. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-05-31 | -79255.64% |
| 2023-05-31 | -79255.64% |
This trend highlights how Cytodyn Inc manages its overall profitability and cost control over time.
Comparing Cytodyn Inc's Net Margin to Peers
To better understand Cytodyn Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Cytodyn Inc (CYDY) | -79255.64% |
| Krystal Biotech Inc (KRYS) | 30.69% |
| Dynavax Technologies Corp (DVAX) | 9.85% |
| Kiniksa Pharmaceuticals Ltd (KNSA) | -10.21% |
| Y-mAbs Therapeutics Inc (YMAB) | -33.83% |
| Atara Biotherapeutics Inc (ATRA) | -66.23% |
Compared to its competitors, Cytodyn Inc's Net Margin is among the lowest compared to peers, which may indicate challenges in controlling expenses or competitive pricing pressures.